Results 221 to 230 of about 3,524,002 (263)

Mucopolysaccharidoses types I and IIIB: gene therapy by lentiviral vectors

open access: yes, 2002
DI DOMENICO C.   +4 more
core   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang   +3 more
wiley   +1 more source

Lysosomal storage diseases [PDF]

open access: yesNature Reviews Disease Primers, 2018
Lysosomal storage diseases (LSDs) are a group of over 70 diseases that are characterized by lysosomal dysfunction, most of which are inherited as autosomal recessive traits. These disorders are individually rare but collectively affect 1 in 5,000 live births. LSDs typically present in infancy and childhood, although adult-onset forms also occur.
Frances Platt   +2 more
exaly   +5 more sources

Lysosomal storage diseases

open access: yesBiochimica Et Biophysica Acta - Molecular Basis of Disease, 1995
V Gieselmann
exaly   +3 more sources

Lysosomal storage diseases

The Biomedical & Life Sciences Collection
Lysosomal storage disorders (LSDs) are a group of inherited metabolic diseases caused by dysfunction of the lysosomal system, with subsequent progressive accumulation of macromolecules, activation of inflammatory response, and cell death. Neurologic damage is almost always present, and it is usually degenerative.
Alessandro P, Burlina   +2 more
  +6 more sources

LYSOSOMAL STORAGE DISEASES

Neuropathology and Applied Neurobiology, 1978
The majority of lysosomal storage diseases affect the central nervous system. Those that reflect a primary lysosomal disorder are associated with genetically determined deficiencies of specific lysosomal enzymes and storage of the relevant substrate. Autofluorescent lipopigments accumulate in the ceroid‐lipofuscinoses, a heterogeneous group of diseases
openaire   +2 more sources

Lysosomal storage diseases

Current Treatment Options in Neurology, 2001
Lysosomal storage disorders (LSDs), over 40 different diseases, are now considered treatable disorders. Only a few short years ago, Lysosomal storage disorders were seen as interesting neurodegenerative disorders without any potential for treatment. Effective treatment strategies such as bone marrow transplantation (BMT), enzyme replacement therapy ...
openaire   +2 more sources

Lysosomal Glycosphingolipid Storage Diseases

Annual Review of Biochemistry, 2019
Glycosphingolipids are cell-type-specific components of the outer leaflet of mammalian plasma membranes. Gangliosides, sialic acid–containing glycosphingolipids, are especially enriched on neuronal surfaces. As amphi-philic molecules, they comprise a hydrophilic oligosaccharide chain attached to a hydrophobic membrane anchor, ceramide.
Bernadette, Breiden, Konrad, Sandhoff
openaire   +2 more sources

Lysosomal Storage Diseases in Adults

Pathology - Research and Practice, 1994
Most lysosomal storage disorders are known as pediatric diseases. In recent years late onset and adult forms of these disorders have been recognized. The adult form of a given lysosomal storage disorder differs from the childhood disease in several respects. Adult disorders are, with some exceptions, less common than the childhood diseases.
openaire   +2 more sources

Home - About - Disclaimer - Privacy